Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2022-04-08 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release dated April 8, 2022, announcing an upcoming interactive webinar/conference call where the Chairman of the Management Board, Christophe Douat, will answer investor questions live on boursorama.com on April 21st. This is an announcement about an event where investors can interact with management, which strongly aligns with the definition of a Call Transcript (CT) if the transcript were present, or more accurately, an announcement related to investor engagement. Since it is an announcement about a live Q&A session with management, it is closely related to investor relations activities. However, none of the codes perfectly fit 'Announcement of an Investor Q&A Session'. Reviewing the options: - ER (Earnings Release): No financial results are announced, only a pipeline update. - CT (Call Transcript): This is an announcement *for* a call, not the transcript itself. - IP (Investor Presentation): This is not a presentation document. - LTR (Legal Proceedings Report): Not relevant. - DIV/NAV/CAP/etc.: Not relevant. The closest fit among the provided options for an announcement concerning direct interaction between management and investors regarding company updates (pipeline progress, strategy) is often categorized under general investor communications. Given the nature of the event (live Q&A with the Chairman of the Management Board), it is a form of direct communication with investors. If this were the transcript, it would be CT. As an announcement *of* an interactive session, it functions similarly to an announcement preceding an earnings call or a special event. Since it is an announcement about a direct engagement event, and not a formal regulatory filing or a report itself, it falls best under a general investor communication category. Given the options, and recognizing that it is an announcement about management speaking directly to investors, it is most closely related to the context of a Call Transcript (CT) or perhaps a general Regulatory Filing (RNS) if no better fit exists. Since it is an announcement about a live Q&A session, it is a form of investor engagement announcement. In many databases, such announcements are grouped with CTs or ERs. Given the specific focus on management answering questions, it is a precursor to a call. However, the 'MENU VS MEAL' rule suggests we look for announcements of reports. This is an announcement of an interactive session. Since it is not a formal report (10-K, IR, AR, etc.), and it is a specific communication event, RNS (Regulatory Filings - fallback) is a safe choice, but CT (Call Transcript) captures the *type* of event being announced. Since the document is short and announces an event, it is not the transcript itself. Therefore, RNS is the most appropriate fallback for a specific, non-report announcement that doesn't fit other categories like ER or DIV. Revisiting the definitions: It is an announcement about management interaction. It is not a formal report. It is not a standard earnings release (ER). It is not a proxy/AGM material. RNS is the general regulatory announcement fallback. I will classify it as RNS as it is a press release announcing an investor event, not the transcript or a formal financial report.
2022-04-08 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated April 1, 2022, and references Article 223-16 of the AMF General Regulation. It explicitly details the number of outstanding shares and total voting rights as of March 31, 2022. This type of regular disclosure concerning share capital and voting rights is a specific regulatory filing requirement, often related to major shareholding notifications or capital structure updates. Given the options, this most closely aligns with a notification regarding changes in significant share ownership or capital structure, which falls under Major Shareholding Notification (MRQ) or potentially Share Issue/Capital Change (SHA). Since it is a monthly update on the total number of shares and voting rights, which is a key component of monitoring ownership thresholds, MRQ is the most appropriate fit among the provided codes, although it is a recurring regulatory disclosure. It is not a full report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). It is a specific regulatory disclosure, making MRQ the best fit for tracking ownership changes.
2022-04-01 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2022, announcing the inclusion of the first participants in a new clinical trial (SAIVE) for Covid-19 prophylaxis. It details the study design, objectives, and next steps, including expected interim data mid-2022. This type of announcement, focusing on operational updates, clinical trial progress, and key scientific developments, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational update rather than a summary of overall financial performance (ER) or a mandatory regulatory filing like a 10-K, and it is a direct announcement of a significant corporate event (clinical trial initiation), it fits best under the general 'Regulatory Filings' (RNS) category as a press release detailing operational progress, or potentially an Earnings Release (ER) if such updates are bundled there. Given the content is purely operational/scientific news rather than financial results highlights, RNS is the most appropriate fallback for a non-standard announcement. However, many companies issue press releases about clinical trial milestones which are often categorized as Earnings Releases (ER) if they are the primary communication vehicle for the period, or RNS if they are purely regulatory/operational. Since it is a formal announcement of a major operational milestone, and not a financial summary, RNS is the safest classification as a general regulatory announcement.
2022-03-28 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated March 28, 2022, announcing that the first participants have been enrolled in the SAIVE study concerning the prophylactic efficacy of ivermectin against Covid-19. It details the study design (multicenter, randomized, double-blind, placebo-controlled), mentions that interim results are expected mid-2022, and discusses MedinCell's long-acting injectable formulation program. This type of announcement, focusing on clinical trial progress, study details, and pipeline updates, is characteristic of an Investor Presentation (IP) or a general press release related to R&D progress. Since it is a detailed update on a specific clinical program and its implications for the company's strategy and future product pipeline, 'Investor Presentation' (IP) is the most fitting category, as these often contain detailed scientific/clinical updates intended for investors, even if formatted as a press release. It is not a formal regulatory filing like 10-K or IR, nor is it a simple earnings release (ER) or a report publication announcement (RPA).
2022-03-28 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the number of shares and voting rights as of a specific date (February 28, 2022). This content directly relates to changes in share capital and voting rights, which aligns with the definition of Share Issue/Capital Change (SHA) or potentially a Major Shareholding Notification (MRQ) if it were about ownership thresholds being crossed. However, since it is a mandatory monthly disclosure of the total capital structure and voting rights, it is most closely related to capital structure updates. Given the options, 'Share Issue/Capital Change' (SHA) is the most appropriate fit for a regular report detailing the total number of shares and voting rights, as this forms the basis of the capital structure.
2022-03-11 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated February 15, 2022, and references Article 223-16 of the AMF General Regulation. It explicitly provides a table showing the total number of shares and voting rights as of January 31, 2022. This content directly relates to changes in share capital and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially 'Major Shareholding Notification' (MRQ) if it were about crossing thresholds, but since it's a standard monthly disclosure of the total count, SHA is the most appropriate fit among the provided options, as it details the composition of the capital structure. It is not a general regulatory filing (RNS) because it fits a specific category.
2022-02-15 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.